Clicky

9 Meters Biopharma, Inc.(NMTR)

Description: 9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.


Keywords: Organ Systems Gastroenterology Biomolecules Glucagon Like Peptide 1 Glp 1 Celiac Disease Short Bowel Syndrome Celiac Glucagon Like Peptide 2

Home Page: www.9meters.com

NMTR Technical Analysis

8480 Honeycutt Road
Raleigh, NC 27615
United States
Phone: 919 275 1933


Officers

Name Title
Mr. John Temperato Pres, CEO & Director
Ms. Bethany Sensenig C.M.A., M.B.A. Chief Financial Officer
Mr. Sireesh Appajosyula Pharm.D. Sr. VP of Corp. Devel. & Operations
Mr. Albert J. Medwar M.B.A., MBA Sr. VP of Investor Relations & Corp. Communications
Jerry Gardner Head of Clinical Strategy
Dr. Patrick H. Griffin Chief Medical Officer
Dr. Nir Barak M.D. Sr. VP of Scientific Affairs
Ms. Sarah Liu M.B.A. Chief Commercial Officer
Dr. Peter H. R. Green M.D. Clinical & Scientific Advisor and Consultant
Mr. Joseph A. Murray M.D. Clinical & Scientific Advisor and Consultant

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.5881
Price-to-Sales TTM: 0
IPO Date: 2016-07-08
Fiscal Year End: December
Full Time Employees: 21
Back to stocks